From Ganfyd

Jump to: navigation, search

Combination of the DOPA decarboxylase inhibitor carbidopa and levodopa used since the early 1970's for the treatment of Parkinsons disease. The original 1:10 ratio developed when levodopa was the only real competitor, admittedly briefly, was shown to be incorrect in most clinical practice by the end of the 1970s[1][2][3] and the 1:4 ratio should be used at the lower doses used in initiation of therapy and is regarded by most as therapeutically equivalent to co-beneldopa[4] at equivalent levodopa dose.